Literature DB >> 18072812

Neurobiological and clinical effects of the antidepressant tianeptine.

Siegfried Kasper1, Bruce S McEwen.   

Abstract

The precise neurobiological processes involved in depression are not clear, but it is recognized that numerous factors are involved, including changes in neurotransmitter systems and brain plasticity. Neuroplasticity refers to the ability of the brain to adapt functionally and structurally to stimuli. Impairment of neuroplasticity in the hippocampus, amygdala and cortex is hypothesized to be the mechanism by which cognitive function, learning, memory and emotions are altered in depression. The mechanisms underlying alterations in neuroplasticity are believed to relate to changes in neurotransmitters, hormones and growth factors. Structural changes in the hippocampus that have been proposed to be associated with depression include dendritic atrophy, reduced levels of cerebral metabolites, decreased adult neurogenesis (generation of new nerve cells) and reduced volume. Increased dendritic branching occurs in the basolateral nucleus of the amygdala. Reduced neuronal size and glial cell density occur in the prefrontal cortex. Clinically, tianeptine is an antidepressant effective in reducing symptoms of depression in mild to moderate-to-severe major depression, including over the long term. Tianeptine is also effective in alleviating the symptoms of depression-associated anxiety. It is generally well tolerated, with little sedation or cognitive impairment. The efficacy profile of tianeptine could be explained by its neurobiological properties observed in animal models. Tianeptine prevents or reverses stress-associated structural and cellular changes in the brain and normalizes disrupted glutamatergic neurotransmission. In particular, in the hippocampus, it prevents stress-induced dendritic atrophy, improves neurogenesis, reduces apoptosis and normalizes metabolite levels and hippocampal volume. Tianeptine also has beneficial effects in the amygdala and cortex and can reverse the effects of stress on neuronal and synaptic functioning. The neurobiological properties of tianeptine may provide an explanation not only for its antidepressant activity, but also for its anxiolytic effects in depressed patients and its lack of adverse effects on cognitive function and memory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18072812     DOI: 10.2165/00023210-200822010-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  80 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine.

Authors:  H Lôo; J Saiz-Ruiz; M Ansseau; R Herrington; A Vaz-Serra; H Dilling; S de Risio
Journal:  J Affect Disord       Date:  1999-12       Impact factor: 4.839

3.  Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression*

Authors:  J. Dalery; V. Dagens-Lafont; C. De Bodinat
Journal:  Hum Psychopharmacol       Date:  2001-01       Impact factor: 1.672

4.  Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments.

Authors:  Julieta Alfonso; Luciana R Frick; Dafne M Silberman; María L Palumbo; Ana M Genaro; Alberto C Frasch
Journal:  Biol Psychiatry       Date:  2005-09-02       Impact factor: 13.382

Review 5.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Neurochemical profile of tianeptine, a new antidepressant drug.

Authors:  G Kato; A F Weitsch
Journal:  Clin Neuropharmacol       Date:  1988       Impact factor: 1.592

7.  Pre-training administration of tianeptine, but not propranolol, protects hippocampus-dependent memory from being impaired by predator stress.

Authors:  Adam M Campbell; Collin R Park; Phillip R Zoladz; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Eur Neuropsychopharmacol       Date:  2007-06-13       Impact factor: 4.600

8.  Tianeptine attenuates stress-induced morphological changes in the hippocampus.

Authors:  Y Watanabe; E Gould; D C Daniels; H Cameron; B S McEwen
Journal:  Eur J Pharmacol       Date:  1992-11-03       Impact factor: 4.432

9.  Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants.

Authors:  Cyril Rocher; Michael Spedding; Carmen Munoz; Thérèse M Jay
Journal:  Cereb Cortex       Date:  2004-02       Impact factor: 5.357

10.  Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus.

Authors:  M T Lowy; L Gault; B K Yamamoto
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

View more
  27 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

Review 2.  Neuroplasticity and major depression, the role of modern antidepressant drugs.

Authors:  Gianluca Serafini
Journal:  World J Psychiatry       Date:  2012-06-22

Review 3.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

4.  fMRI activation in the amygdala and the orbitofrontal cortex in unmedicated subjects with major depressive disorder.

Authors:  Jennifer D Townsend; Nicole K Eberhart; Susan Y Bookheimer; Naomi I Eisenberger; Lara C Foland-Ross; Ian A Cook; Catherine A Sugar; Lori L Altshuler
Journal:  Psychiatry Res       Date:  2010-08-13       Impact factor: 3.222

Review 5.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

Review 6.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression.

Authors:  Britta Haenisch; Andras Bilkei-Gorzo; Marc G Caron; Heinz Bönisch
Journal:  J Neurochem       Date:  2009-08-18       Impact factor: 5.372

8.  Tianeptine in combination with monoamine oxidase inhibitors for major depressive disorder.

Authors:  Edward H Tobe
Journal:  BMJ Case Rep       Date:  2012-10-09

9.  Tianeptine: an antidepressant with memory-protective properties.

Authors:  Phillip R Zoladz; Collin R Park; Carmen Muñoz; Monika Fleshner; David M Diamond
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

Review 10.  The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation.

Authors:  B S McEwen; S Chattarji; D M Diamond; T M Jay; L P Reagan; P Svenningsson; E Fuchs
Journal:  Mol Psychiatry       Date:  2009-08-25       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.